Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Volume 12 Issue 4, October 2018

Volume 12 Issue 4

In this issue...

• Regenerative medicine enters a new era

• Beyond oncology: bispecific antibodies target new areas

• Evolving approaches in cancer immunotherapy

Cover image: Pipette with transparent drop. anyaivanova, Thinkstock.

Regenerative medicine

    Feature

  • News Feature |

    As a result of the recent landmark gene therapy and chimeric antigen receptor T cell approvals, momentum is building in the field of regenerative medicine. Increased funding and regulatory support has brought confidence to developers that are now bringing a new generation of concepts to the clinic.

    • Cormac Sheridan
  • Profiles

  • Advertisement Feature |

    Jaan Biotherapeutics is developing first-in-class therapies that repair damaged heart muscle and treat cardiovascular diseases by reactivating an endogenous regeneration process that has been shut down in the adult human heart during evolution, but is active in human fetal hearts.

    • Jaan Biotherapeutics
  • Advertisement Feature |

    Nutech Mediworld is addressing unmet medical needs including central nervous system disorders and dermatology indications with clinically validated allogenic stem cell therapy.

    • Nutech Mediworld

Evolving approaches in cancer immunotherapy

    Feature

  • News Feature |

    Against the backdrop of a very deep and broad pipeline, the next breakthroughs in the immuno-oncology space will hinge on leveraging partnerships to improve existing therapies and to develop new strategies.

    • Gaspar Taroncher-Oldenburg
  • Profiles

  • Advertisement Feature |

    Swiss-based AMAL Therapeutics is developing KISIMA, a unique protein-based immunization platform capable of producing single therapeutic vaccines for immunotherapy and beyond.

    • AMAL Therapeutics
  • Advertisement Feature |

    Karma Oncology combines a flexible virtual business model with expertise in oncology clinical trials to provide a bespoke contract clinical research service for biotechnology companies globally.

    • Karma Oncology Limited
  • Advertisement Feature |

    BioWin, the health competitiveness cluster of Wallonia, Belgium, is the region’s point of reference across biopharma and medtech. Cancer immunotherapy has rapidly emerged as a focal point of BioWin’s uniquely collaborative ecosystem, owing to the local high density of cancer and immunology players.

    • BioWin asbl
  • Advertisement Feature |

    Melbourne-based Patrys has developed the Deoxymab platform, a unique technology able to produce antibodies that not only target and penetrate cancer cells, but bind to their DNA and block their repair enzymes, halting further progression.

    • Patrys
  • Advertisement Feature |

    The Center of Molecular Immunology, a core institute of the Cuban organization of Biotechnology and Pharmaceutical Industries, BioCubaFarma, specializes in the development and manufacture of monoclonal antibodies, immunomodulators and molecular vaccines for cancer immunotherapy.

    • Partnerships BioCubaFarma
  • Advertisement Feature |

    Pacific Edge’s state-of-the-art suite of bladder cancer detection and management tests are noninvasive, highly effective, and more accurate than other urine-based cancer diagnostic tests, and are now being adopted into the standard of care.

    • Pacific Edge Ltd
  • Advertisement Feature |

    Engineered agonist or antagonist versions of interleukin-2 (IL-2), IL-4, or IL-13 successfully stimulate tumor-killing immune cells or disrupt the tumor microenvironment while they synergize with other cancer immunotherapy platforms for potent, targeted treatment.

    • Medicenna Therapeutics Corporation
  • Advertisement Feature |

    Pelican Therapeutics’ PTX-35, a novel agonist antibody, amplifies CD8+ antitumor T cell responses via a novel costimulatory target.

    • Pelican Therapeutics

Beyond oncology

    Feature

  • Profiles

  • Advertisement Feature |

    YUMAB, a global provider of fully human monoclonal antibody discovery and development, delivers the antibodies closest to germline on the market. The company provides crucial support to innovators such as Singapore-based startup Enleofen Bio, an exciting new player in fibrosis.

    • YUMAB GmbH
  • Advertisement Feature |

    NBE-Therapeutics is developing a novel class of immune-stimulatory antibody drug conjugates (iADCs) that not only target and destroy cancer cells, but also trigger long-lasting antitumor immunity.

    • NBE-Therapeutics Ltd
  • Advertisement Feature |

    The Antibody Lab’s proprietary cell line development technology enables drug developers to move seamlessly from preclinical discovery to manufacture of the biologic for clinical testing. BESTcell clonal Chinese hamster ovary cell lines can be rapidly generated to enable preclinical testing of multiple biologic drug candidates. After selection of the final candidate, the respective cell line can be used to manufacture master cell banks. This revolutionary approach shortens timelines and reduces the reproducibility risk associated with changing the source of the biologic during research and development.

    • The Antibody Lab GmbH

Search

Quick links